Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 5926371

Next Previous
Drug Profile

GSK 5926371

Alternative Names: 1A46; Anti CD19-CD20-CD3 trispecific antibody - GSK; BR-110; CMG-1A46; GSK-5926371

Latest Information Update: 04 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chimagen Biosciences
  • Developer BioRay Pharmaceutical; Chimagen Biosciences; GSK
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoid leukaemia; Non-Hodgkin's lymphoma
  • Phase I Autoimmune disorders

Most Recent Events

  • 27 May 2026 GlaxoSmithKline plans a phase I/II trial for B cell lymphoma (Second-line therapy or greater), in June 2026 (NCT07607925)
  • 10 Feb 2026 Phase-I clinical trials in Autoimmune disorders in Japan (IV) (NCT07371468)
  • 11 Feb 2025 Chimagen Biosciences terminates phase-I/II clinical trials in Non-Hodgkin's lymphoma and Lymphoid leukaemia (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (Parenteral) due to sponsor's research and development strategy adjustment(NCT05348889)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top